Table 1.
Analysis of clinicopathological factors affecting the outcome by meta regression.
| Variable | Moderators | d.f. | Qm | p-value | Variable | Moderators | d.f. | Qm | p-value |
|---|---|---|---|---|---|---|---|---|---|
| 1-year local control | Age | 1(27) | 0.01 | 0.926 | 1-year overall survival | Age | 1(28) | 0.85 | 0.356 |
| Male | 1(25) | 0.68 | 0.409 | Male | 1(26) | 0.50 | 0.479 | ||
| Right adrenal | 1(21) | 0.74 | 0.391 | Right adrenal | 1(22) | 0.00 | 0.969 | ||
| Bilateral | 1(27) | 2.01 | 0.156 | Bilateral | 1(28) | 0.05 | 0.823 | ||
| Concurrent therapy | 1(8) | 2.53 | 0.112 | Concurrent therapy | 1(11) | 0.01 | 0.905 | ||
| SCLC | 1(20) | 4.37 | 0.037 | SCLC | 1(20) | 2.40 | 0.121 | ||
| Melanoma | 1(24) | 0.07 | 0.791 | Melanoma | 1(24) | 1.31 | 0.253 | ||
| Solitary | 1(16) | 2.94 | 0.087 | Solitary | 1(17) | 0.42 | 0.519 | ||
| Synchronous | 1(15) | 1.52 | 0.218 | Synchronous | 1(15) | 0.21 | 0.650 | ||
| Prescribed dose | 1(26) | 1.20 | 0.273 | Prescribed dose | 1(27) | 0.11 | 0.741 | ||
| Fractions | 1(25) | 1.41 | 0.236 | Fractions | 1(26) | 1.80 | 0.180 | ||
| Dose per fraction | 1(26) | 15.10 | <.001 | Dose per fraction | 1(27) | 3.10 | 0.078 | ||
| BED10 | 1(27) | 23.89 | <.001 | BED10 | 1(28) | 1.95 | 0.163 | ||
| PTV | 1(18) | 2.89 | 0.089 | PTV | 1(18) | 0.15 | 0.703 | ||
| GTV | 1(25) | 0.72 | 0.396 | GTV | 1(26) | 1.98 | 0.160 | ||
| Tumor size | 1(7) | 0.03 | 0.861 | Tumor size | 1(7) | 0.52 | 0.473 | ||
| Tracking technology | 1(25) | 3.31 | 0.069 | Tracking technology | 1(26) | 5.73 | 0.017 | ||
| 2-year local control | Age | 1(24) | 0.17 | 0.684 | 2-year overall survival | Age | 1(27) | 2.40 | 0.121 |
| Male | 1(22) | 0.48 | 0.490 | Male | 1(25) | 0.02 | 0.895 | ||
| Right adrenal | 1(18) | 0.51 | 0.473 | Right adrenal | 1(21) | 0.39 | 0.534 | ||
| Bilateral | 1(24) | 1.02 | 0.313 | Bilateral | 1(27) | 1.33 | 0.249 | ||
| Concurrent therapy | 1(8) | 0.09 | 0.761 | Concurrent therapy | 1(11) | 1.65 | 0.199 | ||
| SCLC | 1(17) | 0.03 | 0.871 | SCLC | 1(19) | 10.04 | 0.002 | ||
| Melanoma | 1(21) | 1.03 | 0.310 | Melanoma | 1(23) | 0.03 | 0.863 | ||
| Solitary | 1(15) | 1.85 | 0.174 | Solitary | 1(17) | 0.68 | 0.409 | ||
| Synchronous | 1(13) | 0.32 | 0.570 | Synchronous | 1(15) | 1.69 | 0.194 | ||
| Prescribed dose | 1(23) | 0.82 | 0.365 | Prescribed dose | 1(26) | 0.10 | 0.755 | ||
| Fractions | 1(22) | 0.23 | 0.629 | Fractions | 1(25) | 3.21 | 0.073 | ||
| Dose per fraction | 1(23) | 1.35 | 0.245 | Dose per fraction | 1(26) | 6.60 | 0.010 | ||
| BED10 | 1(24) | 7.72 | 0.006 | BED10 | 1(27) | 2.82 | 0.093 | ||
| PTV | 1(16) | 0.47 | 0.491 | PTV | 1(17) | 4.87 | 0.027 | ||
| GTV | 1(24) | 0.13 | 0.718 | GTV | 1(26) | 8.20 | 0.004 | ||
| Tumor size | 1(6) | 1.42 | 0.233 | Tumor size | 1(7) | 1.27 | 0.261 | ||
| Tracking technology | 1(22) | 0.34 | 0.559 | Tracking technology | 1(25) | 8.75 | 0.003 |
SCLC, small cell lung cancer; PTV, planning target volume; GTV, gross tumor volume. The red shading mean that significantly difference (p <0.05).